Cervical cancer is a preventable disease, yet it remains a leading cause of cancer death among women worldwide. The quadrivalent HPV vaccine is a safe and effective vaccine that can protect against the four most common HPV types that cause cervical cancer.

This randomized vaccination study aims to provide scientific evidence on the comparative efficacy of a two-dose HPV vaccination regimen compared to the current standard three-dose regimen. The study will also assess the vaccine’s ability to induce and sustain immunogenicity, immune memory, prevent infection by HPV types included in the vaccine, and provide cross-protection against HPV types not included in the vaccine.

The overall goal of this project is to accelerate access to HPV vaccine in India and other developing countries by guiding public health policies for planning and implementing large-scale, sustained HPV vaccination programs to prevent cervical cancer.